Screening for Liver Cancer in HIV/HCV Coinfected People
- Details
- Category: Liver Cancer/HCC
- Published on Friday, 28 May 2010 23:40
- Written by Liz Highleyman
Nearly half of HIV/HCV coinfected individuals with liver cancer in an international study were never screened for hepatocellular carcinoma, but those who did undergo screening had their cancer detected at an earlier stage, leading to more effective treatment and improved survival, according to a report presented at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) last month in Vienna.
Rifaximin Reduces Encephalopathy Recurrence, Improves Quality of Life in People with Liver Cirrhosis
- Details
- Category: Decompensation & ESLD
- Published on Friday, 28 May 2010 20:23
- Written by Liz Highleyman
The broad-spectrum antibiotic rifaximin (Xifaxan) improves quality of life for people with liver cirrhosis who experience recurrent episodes of hepatic encephalopathy, or brain disease, according to research presented at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) last month in Vienna. Another analysis from the same study indicated that rifaximin works by lowering the level of ammonia in the blood.
EASL 2010: Spontaneous Undetectable Hepatitis B Virus DNA Is Uncommon, especially without HBeAg Clearance
- Details
- Category: HBV Treatment
- Published on Friday, 14 May 2010 19:17
- Written by Liz Highleyman
Clearance of hepatitis B virus (HBV) DNA from the blood seldom occurs without treatment even after a decade, researchers reported at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) last month in Vienna. Among people who experience hepatitis B "e" antigen (HBeAg) clearance, however, the likelihood of also achieving undetectable viral load was higher, approaching 50% at 10 years.
EASL 2010: Achillion Announces Additional Promising Data from Phase 1b Trial of HCV Protease Inhibitor ACH-1625
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 21 May 2010 13:56
- Written by Achillion Pharmaceuticals
Achillion Pharmaceuticals this month announced further interim data from an ongoing Phase 1b trial of the company's investigational hepatitis C virus (HCV) NS3 protease inhibitor ACH-1625. At the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) last month in Vienna, researchers presented early data showing that in patients with genotype 1 chronic hepatitis C, ACH-1625 monotherapy at doses of 500 mg and 600 mg twice-daily for 5 days decreased HCV viral load by approximately 4 log and was generally well-tolerated with no drug-related serious adverse events. The latest data extend these findings to people taking doses of 200 mg twice-daily and 600 mg once-daily.
EASL 2010: Measurable Neurocognitive Impairment Persists after Episodes of Hepatic Encephalopathy in People with Liver Cirrhosis
- Details
- Category: HBV Disease Progression
- Published on Tuesday, 11 May 2010 12:56
- Written by Liz Highleyman
Changes in working memory, psychomotor speed, and other neurocognitive measures persist in patients with hepatic encephalopathy due to decompensated liver cirrhosis, according to research presented at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) last month in Vienna. A related study presented at the Digestive Disease Week conference (DDW 2010) last week in New Orleans found that more than half of people with compensated cirrhosis (mostly due to hepatitis C) showed signs of neurocognitive impairment, indicating that mild hepatic encephalopathy is common even among individuals without severe liver disease.
More Articles...
- EASL 2010: European Study Finds More than Half of HIV/HCV Coinfected Patients Do Not Receive Treatment despite Advanced Fibrosis
- Longer Treatment with Pegylated Interferon Works Better for Hepatitis B Genotype D
- EASL 2010: HIV/HCV Coinfected Patients with Acute Hepatitis C Are Equally Likely to Achieve Sustained Response with Interferon plus Ribavirin
- EASL 2010: PROTECT Study Finds One-third of Liver Transplant Patients Achieve Sustained Response to Pegylated Interferon plus Ribavirin
- EASL 2010: Tenofovir (Viread) Effective for Treatment of Chronic Hepatitis B Patients with Suboptimal Response to Adefovir (Hepsera)
- EASL 2010: HIV and Hepatitis C Virus Coinfection May Increase Death of CD4 T-cells
- EASL 2010: MARS and Prometheus Artificial Liver Devices Offer Some Benefits for Patients with Liver Failure, but Did Not Improve Survival
- EASL 2010: HBV DNA and HBsAg Levels Predict Likelihood of Sustained Response to Pegylated Interferon for Hepatitis B
- EASL 2010: Child-Pugh Score Changes Do Not Predict Liver Failure among HIV/HCV Coinfected Patients during Hepatitis C Treatment
- EASL 2010: Tenofovir (Viread) Demonstrates High Barrier to Resistance over 3 Years in Chronic Hepatitis B Patients
- EASL 2010: Tenofovir/emtricitabine (Truvada) Prevents Hepatitis B Recurrence after Liver Transplantation in Patients with Mild Kidney Impairment
- EASL 2010: World Hepatitis Alliance Releases Major Report on Viral Hepatitis Policy at EASL Meeting
- EASL 2010: Biopsy Study Suggests Liver Disease Does Not Progress Faster in HIV/HCV Coinfected People
Web Design and Development by